1. Despite waning effectiveness against SARS-CoV-2 infection, fully vaccinated patients continued to show low COVID-19 hospitalization rates up to 5 ...
1. The primary outcome of mortality or dependency was greater in patients with VITT-associated CVT compared to non-VITT CVT (p=0.0061). ...
1. A case series of 22 patients found that women and patients with an allergy history were more likely to ...
1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody ...
1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of ...
1. An interim analysis of post-vaccination surveillance data for individuals who had received either Pfizer or Moderna mRNA COVID-19 vaccinations ...
1. The findings of this prospective cohort study suggested poor humoral immune response following a single dose of the BNT162b2 ...
1. Incidence of PCR-confirmed symptomatic COVID-19 cases was lower in the vaccine group compared with the placebo group (p<0.0001). 2. ...
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 ...
1. After receiving the BNT162b2 SARS-CoV-2 vaccine, fewer cancer patients demonstrated seropositivity for COVID antibodies compared to age-matched healthy controls, ...
